Cargando…

Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis

Many laboratories validate DST of the second-line drugs by BACTEC MGIT 960 system. The objective of this study is to evaluate the critical concentration and perform DST for the 2nd line drugs. We evaluated 193 clinical strains of M. tuberculosis isolated from patients in South Korea. Testing the cri...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyejin, Seo, Minji, Park, Young Kil, Yoo, Jae-Il, Lee, Yeong Seon, Chung, Gyung Tae, Ryoo, Sungweon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628654/
https://www.ncbi.nlm.nih.gov/pubmed/23606961
http://dx.doi.org/10.1155/2013/108401
_version_ 1782266448921493504
author Kim, Hyejin
Seo, Minji
Park, Young Kil
Yoo, Jae-Il
Lee, Yeong Seon
Chung, Gyung Tae
Ryoo, Sungweon
author_facet Kim, Hyejin
Seo, Minji
Park, Young Kil
Yoo, Jae-Il
Lee, Yeong Seon
Chung, Gyung Tae
Ryoo, Sungweon
author_sort Kim, Hyejin
collection PubMed
description Many laboratories validate DST of the second-line drugs by BACTEC MGIT 960 system. The objective of this study is to evaluate the critical concentration and perform DST for the 2nd line drugs. We evaluated 193 clinical strains of M. tuberculosis isolated from patients in South Korea. Testing the critical concentration of six second-line drugs was performed by MGIT 960 and compared with L-J proportion method. The critical concentration was determined to establish the most one that gave the difference between drug resistance and susceptibility in MGIT960 system. Good agreement of the following concentrations was found: Concordance was 95% for 0.5 μg/mL of moxifloxacin; 93.6%, 1.0 μg/mL of levofloxacin; 97.5%, 2.5 μg/mL of kanamycin; 90.6%, 2.5 μg/mL of capreomycin; 86.2%, 5.0 μg/mL of ethionamide; and 90.8%, 2.0 μg/mL of ρ-aminosalicylic acid. The critical concentrations of the four drugs, moxifloxacin, levofloxacin, kanamycin, and capreomycin, were concordant and reliable for testing 2nd line drug resistance. Further study of ethionamide and ρ-aminosalicylic acid is required.
format Online
Article
Text
id pubmed-3628654
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-36286542013-04-19 Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis Kim, Hyejin Seo, Minji Park, Young Kil Yoo, Jae-Il Lee, Yeong Seon Chung, Gyung Tae Ryoo, Sungweon Tuberc Res Treat Research Article Many laboratories validate DST of the second-line drugs by BACTEC MGIT 960 system. The objective of this study is to evaluate the critical concentration and perform DST for the 2nd line drugs. We evaluated 193 clinical strains of M. tuberculosis isolated from patients in South Korea. Testing the critical concentration of six second-line drugs was performed by MGIT 960 and compared with L-J proportion method. The critical concentration was determined to establish the most one that gave the difference between drug resistance and susceptibility in MGIT960 system. Good agreement of the following concentrations was found: Concordance was 95% for 0.5 μg/mL of moxifloxacin; 93.6%, 1.0 μg/mL of levofloxacin; 97.5%, 2.5 μg/mL of kanamycin; 90.6%, 2.5 μg/mL of capreomycin; 86.2%, 5.0 μg/mL of ethionamide; and 90.8%, 2.0 μg/mL of ρ-aminosalicylic acid. The critical concentrations of the four drugs, moxifloxacin, levofloxacin, kanamycin, and capreomycin, were concordant and reliable for testing 2nd line drug resistance. Further study of ethionamide and ρ-aminosalicylic acid is required. Hindawi Publishing Corporation 2013 2013-03-28 /pmc/articles/PMC3628654/ /pubmed/23606961 http://dx.doi.org/10.1155/2013/108401 Text en Copyright © 2013 Hyejin Kim et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Kim, Hyejin
Seo, Minji
Park, Young Kil
Yoo, Jae-Il
Lee, Yeong Seon
Chung, Gyung Tae
Ryoo, Sungweon
Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis
title Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis
title_full Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis
title_fullStr Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis
title_full_unstemmed Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis
title_short Evaluation of MGIT 960 System for the Second-Line Drugs Susceptibility Testing of Mycobacterium tuberculosis
title_sort evaluation of mgit 960 system for the second-line drugs susceptibility testing of mycobacterium tuberculosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3628654/
https://www.ncbi.nlm.nih.gov/pubmed/23606961
http://dx.doi.org/10.1155/2013/108401
work_keys_str_mv AT kimhyejin evaluationofmgit960systemforthesecondlinedrugssusceptibilitytestingofmycobacteriumtuberculosis
AT seominji evaluationofmgit960systemforthesecondlinedrugssusceptibilitytestingofmycobacteriumtuberculosis
AT parkyoungkil evaluationofmgit960systemforthesecondlinedrugssusceptibilitytestingofmycobacteriumtuberculosis
AT yoojaeil evaluationofmgit960systemforthesecondlinedrugssusceptibilitytestingofmycobacteriumtuberculosis
AT leeyeongseon evaluationofmgit960systemforthesecondlinedrugssusceptibilitytestingofmycobacteriumtuberculosis
AT chunggyungtae evaluationofmgit960systemforthesecondlinedrugssusceptibilitytestingofmycobacteriumtuberculosis
AT ryoosungweon evaluationofmgit960systemforthesecondlinedrugssusceptibilitytestingofmycobacteriumtuberculosis